 |
138 Diseases |  |
93 Trials |
|
93 Trials |  |
2195 News |  |
| «12...22232425262728293031323334 |
- || everolimus / Generic mfg.
New P3 trial: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Aug 26, 2012
P3, N=3500, Recruiting, Sponsor: Southwest Oncology Group
- pazopanib / Generic mfg.
Enrollment closed: Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer (clinicaltrials.gov) - Aug 23, 2012
P2, N=98, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting
- leuprorelin depot / Generic mfg.
Clinical: Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation (clinicaltrials.gov) - Aug 19, 2012
P=N/A, N=40, Recruiting, Sponsor: Main Line Fertility Center
- | thalidomide / Generic mfg.
Enrollment change: Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer (clinicaltrials.gov) - Aug 12, 2012
P3, N=159, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting N=101 --> 159
- letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Enrollment change: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Jul 18, 2012
P2, N=84, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=101 --> 159 N=28 --> 84
- | letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
New P2 trial: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Jul 15, 2012
P2, N=84, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- New P4 trial: The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty (clinicaltrials.gov) - Jul 4, 2012
P4, N=0, Active, not recruiting, Sponsor: Daewoong Pharmaceutical Co. LTD.
- || leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed, Metastases: Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=300, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=28 --> 84 Recruiting --> Active, not recruiting
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=391, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | orteronel (TAK 700) / Takeda
Enrollment open: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Jun 9, 2012
P3, N=900, Recruiting, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg., anastrozole / Generic mfg., testosterone gel / Generic mfg.
Trial completion: Regulation of Cortisol Metabolism and Fat Patterning (clinicaltrials.gov) - Jun 3, 2012
P=N/A, N=140, Completed, Sponsor: Oregon Health and Science University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- leuprolide acetate for depot suspension / Generic mfg.
Gene Expression Profile, Biopsy: Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation (clinicaltrials.gov) - May 24, 2012
P=N/A, N=20, Enrolling by invitation, Sponsor: University of Connecticut Health Center
- Cetrotide (cetrorelix) / EMD Serono
Enrollment open: Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity (clinicaltrials.gov) - May 23, 2012
P=N/A, N=300, Recruiting, Sponsor: Southern Cross Fertility Centre
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment change: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - May 21, 2012
P2, N=47, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Recruiting N=38 --> 47
- docetaxel / Generic mfg.
Enrollment closed, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Apr 25, 2012
P1, N=36, Active, not recruiting, Sponsor: Medical University of South Carolina
N=38 --> 47 Recruiting --> Active, not recruiting
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed: Impact of Hot Flashes on Sleep and Mood Disturbance (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=50, Active, not recruiting, Sponsor: Hadine Joffe, MD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment change: GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients (clinicaltrials.gov) - Apr 15, 2012
P2, N=60, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=75 --> 60
- |||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-na (clinicaltrials.gov) - Apr 5, 2012
P3, N=164, Recruiting, Sponsor: Takeda
N=75 --> 60 Not yet recruiting --> Recruiting
- |||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy (clinicaltrials.gov) - Apr 5, 2012
P3, N=164, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Apr 3, 2012
P2, N=450, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg.
Trial withdrawal: Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy (clinicaltrials.gov) - Mar 19, 2012
P4, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting Completed --> Withdrawn
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment change: Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy (clinicaltrials.gov) - Mar 19, 2012
P4, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Completed --> Withdrawn N=108 --> 0
- |||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Metastases: Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer (clinicaltrials.gov) - Mar 14, 2012
P1/2, N=100, Completed, Sponsor: Mayo Clinic
N=108 --> 0 Active, not recruiting --> Completed
- |||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Metastases: Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer (clinicaltrials.gov) - Mar 14, 2012
P2, N=112, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || orteronel (TAK 700) / Takeda
New P3 trial: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Mar 5, 2012
P3, N=900, Recruiting, Sponsor: Radiation Therapy Oncology Group
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-na (clinicaltrials.gov) - Mar 5, 2012
P3, N=164, Recruiting, Sponsor: Takeda
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy (clinicaltrials.gov) - Mar 5, 2012
P3, N=164, Recruiting, Sponsor: Takeda
- ||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P2 trial: Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer (clinicaltrials.gov) - Mar 5, 2012
P2, N=52, Completed, Sponsor: Medivation, Inc.
- | leuprolide acetate for depot suspension / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment open: LUPRON: GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases (clinicaltrials.gov) - Feb 28, 2012
P3, N=75, Recruiting, Sponsor: Joseph Mccune
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Capesaris (GTx-758) / Oncternal Therap
Trial termination: Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer (clinicaltrials.gov) - Feb 20, 2012
P2, N=156, Terminated, Sponsor: GTx
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; FDA Clinical Hold
- | leuprolide acetate for depot suspension / Generic mfg., norethindrone / Generic mfg.
Enrollment closed: Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) (clinicaltrials.gov) - Feb 9, 2012
P3, N=112, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Terminated; FDA Clinical Hold Recruiting --> Active, not recruiting
- New P2 trial, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - Feb 8, 2012
P2, N=2, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy (clinicaltrials.gov) - Feb 1, 2012
P3, N=386, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- MVT-602 / Sumitomo Pharma
Enrollment change: Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 (clinicaltrials.gov) - Jan 25, 2012
P1/2, N=9, Terminated, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=99 --> 9
- | Suprefact (buserelin acetate) / Sanofi
Enrollment open: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Jan 24, 2012
P3, N=192, Recruiting, Sponsor: Proton Collaborative Group
N=99 --> 9 Not yet recruiting --> Recruiting
- Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer (clinicaltrials.gov) - Jan 17, 2012
P1, N=22, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Suprefact (buserelin acetate) / Sanofi
Trial completion, Surgery: SWOG-JPR3: Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jan 8, 2012
P3, N=361, Completed, Sponsor: NCIC Clinical Trials Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Suprefact (buserelin acetate) / Sanofi
New P3 trial: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Dec 13, 2011
P3, N=192, Recruiting, Sponsor: Proton Collaborative Group
- leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Enrollment change, Metastases: Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer (clinicaltrials.gov) - Dec 12, 2011
P2, N=0, Withdrawn, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed N=132 --> 0
- | docetaxel / Generic mfg.
New P2 trial: The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer (clinicaltrials.gov) - Dec 4, 2011
P2, N=90, Recruiting, Sponsor: Asan Medical Center
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., flutamide / Generic mfg.
Trial completion: Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer (clinicaltrials.gov) - Nov 20, 2011
P3, N=2028, Completed, Sponsor: Radiation Therapy Oncology Group
N=132 --> 0 Active, not recruiting --> Completed
- Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer (clinicaltrials.gov) - Nov 17, 2011
P1, N=22, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=18 --> 22
- ||||||| Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company
Trial completion: PEARLII: PGL4001 Versus GnRH-agonist in Uterine Myomas (clinicaltrials.gov) - Nov 9, 2011
P3, N=301, Completed, Sponsor: PregLem SA
N=18 --> 22 Active, not recruiting --> Completed
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P2 trial: Efficacy and Safety of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Oct 20, 2011
P2, N=487, Completed, Sponsor: Takeda
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P2 trial: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Oct 13, 2011
P2, N=450, Recruiting, Sponsor: Takeda
- | leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: DUALTRIGGER: Study of Dual Trigger Ovulation in Oocyte Donors (clinicaltrials.gov) - Sep 27, 2011
P4, N=180, Recruiting, Sponsor: Weill Medical College of Cornell University
- MVT-602 / Sumitomo Pharma
Trial termination: Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 (clinicaltrials.gov) - Aug 25, 2011
P1/2, N=9, Terminated, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Terminated; Developing new formulation of study drug. New study to open next year under a new protocol.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer (clinicaltrials.gov) - Aug 10, 2011
P3, N=160, Active, not recruiting, Sponsor: GP-Pharm